207,887 Shares in IQVIA Holdings Inc. $IQV Bought by Ruffer LLP

Key Points

• Ruffer LLP has acquired 207,887 shares of IQVIA Holdings Inc., valued at approximately $32.76 million, making IQVIA the firm's 17th largest holding.
• Insider transactions reveal that key executives, including Keriann Cherofsky and Eric Sherbet, have recently sold portions of their holdings, resulting in a decline in their ownership percentages.
• IQVIA reported better-than-expected earnings of $2.81 EPS for the recent quarter, exceeding analyst estimates, while the stock has received multiple analyst upgrades, increasing its price target significantly.

Ruffer LLP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 207,887 shares of the medical research company's stock, valued at approximately $32,760,000. IQVIA makes up about 1.4% of Ruffer LLP's investment portfolio, making the stock its 17th largest holding. Ruffer LLP owned 0.12% of IQVIA at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. American National Bank & Trust acquired a new position in shares of IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of IQVIA during the first quarter worth about $33,000. Finally, ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $181.25 on Thursday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $30.81 billion, a P/E ratio of 26.23, a PEG ratio of 2.05 and a beta of 1.32. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $238.56. The company has a 50-day moving average price of $186.37 and a 200 day moving average price of $167.39.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and raised their price objective for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Barclays raised their price objective on IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Mizuho increased their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, UBS Group increased their target price on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.